跳至主要内容
临床试验/NCT01720056
NCT01720056终止4 期

Assessment of Verapamil as an Adjunct for Prevention of Keloid Recurrence After Surgical Removal

The University of Western Australia1 个研究点 分布在 1 个国家目标入组 14 人开始时间: 2012年10月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
终止
入组人数
14
试验地点
1
主要终点
Keloid recurrence

研究概览

简要总结

Keloid scarring is a severe cosmetic and painful disease of the skin. The gold standard treatment is yet to be clarified. This randomized clinical pilot study will compare the effects of two local treatments for preventing keloid recurrence after surgical removal; steroid and verapamil.

Study hypothesis: Intralesional therapy with the calcium antagonist verapamil has equal treatment efficacy as steroid injection.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Double (Participant, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient undergoing surgical removal of keloid
  • Patient 18 years old or greater
  • Length of excisional scar after surgical removal of keloid between 2 and 10 cm

排除标准

  • Keloid in face or hands
  • Pregnancy or lactation
  • Any heart or pulmonary condition
  • Systemic treatment with beta-blockers, ACE-inhibitors or calcium antagonists
  • Systemic corticosteroidal therapy
  • Intralesional steroid treatment within 2 months of surgery to remove keloid
  • Flap surgery
  • Lesions to face, hands and other cosmetically sensitive areas

研究组 & 干预措施

Verapamil

Active Comparator

Verapamil 2.5 mg/mL injection sc intralesionally

干预措施: Verapamil (Drug)

Kenalog 10

Active Comparator

Kenalog 10 mg/mL injection sc intralesionally

干预措施: Kenalog 10 (Drug)

结局指标

主要结局

Keloid recurrence

时间窗: 1 year

次要结局

  • Vancouver Scar Scale Score(1 year)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Fiona M. Wood

Prof. Wood

The University of Western Australia

研究点 (1)

Loading locations...

相似试验